ISRCTN68358784已完成未知
A Randomised Controlled double-blind clinical Trial to evaluate the safety and performance of Neuromuscular Electrical Stimulation (NMES) with the NeuroTech Vital device for the treatment of stress urinary incontinence (SUI)
Bio-Medical Research Ltd (Ireland)0 个研究点目标入组 140 人开始时间: 2013年7月30日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •1. Subjects who are female and at least 18 years of age
- •2. Subjects who have signed informed consent form prior to any study related activity
- •3. Subjects who have previously failed a 6 week volitional pelvic floor muscle training programme or in the Investigators opinion an equivalent lifestyle and exercise programme
- •4. Subjects who have been clinically diagnosed with stress urinary incontinence and demonstrate a >4g urine leakage following a standardised 1-minute stress test at 1 hour post-bladder filling protocol (1-hour pad weight test). Stress urinary incontinence is defined as complaint of involuntary leakage on effort or exertion, or on sneezing and coughing? (International Continence Society)
- •5. Subjects who are confirmed as having predominant stress urinary incontinence on the Medical, Epidemiologic and Social Aspects of Aging Urinary Incontinence (MESA) Questionnaire completed at the screening assessment
- •6. Subjects with a Body Mass Index of = 40 kg/m2
- •7. Subjects who are able to give voluntary, written informed consent to participate in this study and from whom consent has been obtained
- •8. Subjects who are able to understand this study and are willing to complete all the study assessments
排除标准
- •1. Subjects who have an existing medical condition that would compromise their participation in the study
- •2. Subjects who have a physical condition that would make them unable to perform the study procedures
- •3. Subjects who have been diagnosed with Chronic Obstructive Pulmonary Disease (COPD)
- •4. Subjects with a history of an underlying neurological condition
- •5. Subjects with a history of low back pain involving the spinal nerve root
- •6. Subjects who are currently taking medication, or have taken medication in the last 4 weeks, for urinary incontinence or that effect urinary output function including anti-cholinergics or anti-histamines or any anti-anxiety medications
- •7. Subjects with a blood clotting disorder or who are taking anti-coagulant medications
- •8. Subjects who have previously had any uro-gynaecological related surgery that would affect the pelvic floor muscles or urinary flow through the urethra (excluding hysterectomy)
- •9. Subjects with a clinical diagnosis of prolapse greater than Stage 2
- •10. Subjects who are pregnant or could be pregnant
- •11. Subjects who are less than 6 months post-partum or who are lactating
- •12. Subjects who have any intra-uterine devices or metal implants in the pelvic area, including hip and lumbar spine
- •13. Subjects with pelvic pain or fibromyalgia or paravaginal defect
- •14. Subjects with an active implanted medical device (i.e. pacemaker, pump etc)
- •15. Subjects with a current or active history of pelvic cancer and/or subjects with a life expectancy of less than 12 months
- •16. Subjects with an injury or disability affecting any part of their body which will be in contact with the garment
- •17. Subjects who are currently involved in any injury litigation claims
- •18. Subjects who have participated in a clinical study in the last 3 months or any previous clinical study with Bio-Medical Research Ltd
- •19. Subjects who have been committed to an institution by virtue of an order issued either by the courts or by an authority
- •20. Any vulnerable subjects defined as individuals whose willingness to volunteer in a clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate. Examples are members of a group with a hierarchical structure, such as medical, pharmacy, dental and nursing students, subordinate hospital and laboratory personnel, employees of the pharmaceutical and medical device industry, members of the armed forces, and persons kept in detention. Other vulnerable subjects include patients with incurable diseases, persons in nursing homes, unemployed or impoverished persons, patients in emergency situations, ethnic minority groups, homeless persons, nomads, refugees, minors, and those incapable of giving consent
研究者
相似试验
招募中
3 期
A plant based Ayurvedic medicine used for the prevention and management of various risk factors responsible for occurrence of Coronary Heart Disease.CTRI/2015/01/005397Department of Science Technology1,000
进行中（未招募）
2 期
Comparison of ethanol lock vs heparin lock in catheter infection treatmentCTRI/2023/06/053826Vignesh Subramani
已完成
不适用
A double-blind randomised controlled clinical trial of levosimendan vs dopexamine in septic shockSepsisISRCTN46862968Record Provided by the NHSTCT Register - 2006 Update - Department of Health20
终止
4 期
A clnical trIal comparing the effect of treatment with oral spironolactone compared with a placebo on the frequency and duration of atrIal fibrillation in patients with an implanted cardiac device in New Zealand.Atrial FibrillationACTRN12616001188426niversity of Otago150
终止
3 期
A Study to Compare Loperimide to Placebo for the Prevention of Excess Fluid Losses From the Stoma in Patients with New Loop Ileostomy.ACTRN12614000180617Hunter New England Local Health District86